Physician experience with once-weekly somatrogon versus once-daily rhGH regimen in pediatric patients with growth hormone deficiency: a cross-sectional survey of physicians from the global phase 3 study
IntroductionThe standard of care for pediatric growth hormone deficiency (pGHD) is once-daily recombinant human growth hormone (rhGH). Somatrogon, a long-acting rhGH, requires less frequent, once-weekly, dosing. We describe physicians’ preference for, experiences, and satisfaction with once-weekly s...
Main Authors: | Roy Gomez, Roger Lamoureux, Diane M. Turner-Bowker, Jane Loftus, Mohamad Maghnie, Bradley S. Miller, Michel Polak, Andrew Yaworsky |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-10-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2023.1254424/full |
Similar Items
-
Patients with Growth-Related Disorders and Caregivers Prefer the Somapacitan Device to the Somatrogon Device: Results from a Randomized Crossover Study Assessing Device Preference and Ease of Use Following Simulated Injections
by: Akhtar S, et al.
Published: (2024-10-01) -
Self-reported vs electronically-recorded adherence to GH therapy
by: Mynor Alvarez, et al.
Published: (2022-02-01) -
Investigating significant health trends in growth hormone treatments registry: rationale, aims and design of a nationwide prospective registry (study protocol)
by: Dirk Schnabel, et al.
Published: (2023-05-01) -
The efficacy and safety of rhGH treatment combined with letrozole/GnRHa in adolescent boys
by: Ying Zhang, et al.
Published: (2025-01-01) -
Does excessive body mass affect the rhGH therapy outcomes in GHD children?
by: Tomasz Maroszczuk, et al.
Published: (2024-10-01)